Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, M.D., to the Board of Directors
March 08, 2022 07:30 ET
|
Affinia Therapeutics
WALTHAM, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene...
Affinia Therapeutics Appoints Thomas Leggett as Chief Financial Officer
December 14, 2021 08:00 ET
|
Affinia Therapeutics
WALTHAM, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene...
Affinia Therapeutics Appoints Carole Faig to Board of Directors
October 06, 2021 07:30 ET
|
Affinia Therapeutics
WALTHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene...
Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group
September 08, 2021 07:30 ET
|
Affinia Therapeutics
Indications include metachromatic leukodystrophy, a rare, progressive, and fatal disease affecting the nervous system, and brain metastases secondary to HER2+ breast cancer, a common and deadly form...
Affinia Therapeutics Announces Collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB) To Rationally Design Novel CNS Promoters for Gene Therapy
July 20, 2021 07:10 ET
|
Affinia Therapeutics
– Botond Roska, M.D., Ph.D., world-renowned scientist and Director at IOB and scientific co-founder of Affinia Therapeutics, will oversee collaboration – – Collaboration will expand upon company’s...
Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting
May 13, 2021 06:30 ET
|
Affinia Therapeutics
WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and...
Affinia Therapeutics Closes $110 Million Series B Financing
May 03, 2021 06:30 ET
|
Affinia Therapeutics
Financing co-led by EcoR1 Capital and Farallon Capital ManagementProceeds to support continued development of proprietary platform for rationally designed adeno-associated virus vectors (AAV) and...
Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting
April 27, 2021 16:30 ET
|
Affinia Therapeutics
WALTHAM, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors...
Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic
February 17, 2021 06:30 ET
|
Affinia Therapeutics
-- Gene editing expert Charles Albright, Ph.D., joins as chief scientific officer -- -- Gene therapy development expert Petra Kaufmann, M.D., joins as chief medical officer – WALTHAM, Mass., Feb. ...
Affinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Company’s Board of Directors
June 08, 2020 07:00 ET
|
Affinia Therapeutics
WALTHAM, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene...